For Immediate Release - April 30, 2008

BEDFORD, Mass. (April 30, 2008) - Hologic, Inc. (NASDAQ: HOLX), a diversified medical technologies company specializing in diagnostics, imaging systems and interventional devices dedicated to serving the healthcare needs of women, announced at the American Society of Breast Surgeons conference in New York City that U.S. breast surgeons are among the first to realize the substantial benefits of product integrations resulting from recent company mergers, acquisitions and partnerships.

The Suros® Celero™ spring-loaded, vacuum assisted core biopsy device, SecurMark™ for Celero biopsy site identifier, MammoSite® 5-day radiation therapy system, and a recent agreement with Mindray Medical International to sell the to DP-6600 digital ultrasonic diagnostic imaging system, allows Hologic to offer a comprehensive ultrasound-guided portfolio to the U.S. breast surgery market.

“With Hologic offering a full line of ultrasound breast care products, we are able to drastically shorten the time it takes from performing an abnormal ultrasound biopsy to giving the patient a diagnosis,” said Thomas Heck, MD, FACS, Medical Director of the Samaritan Breast Center in Dayton, Ohio. “The waiting period is sometimes now just one day. This is a huge help in significantly lowering patient anxiety.”

“This product integration provides a meaningful solution in meeting the needs of breast surgeons and also has the potential of significantly improving patient care,” said David Harding, President of the Interventional Breast Solutions Business Unit of Hologic. “Our Mindray partnership, combined with innovative product lines, allows us to change the way ultrasound-guided breast biopsy, diagnostic imaging, and placement of the MammoSite radiation therapy system can be performed in the physician’s office. We have also added convenience for the breast surgeon by making these products available through a single contact – our breast surgery sales specialists.”

SecurMark biopsy site identifiers are one of Hologic’s newest product releases. SecurMark identifiers use a biocompatible titanium clip surrounded by a bio-absorbable suture-like material designed to minimize marker movement within the biopsy cavity and help visualize the marker under traditionally challenging circumstances in the ultrasound environment. SecurMark site identifiers preliminarily indicates visibility 2-3 weeks after deployment, making it effective for surgeons in accurately guiding them with wire localization should a follow up lumpectomy be necessary. After 4 months, the Glycoprene® netting surrounding the marker shows no visual evidence and is safely and fully absorbed into the body. SecurMark for Celero site identifiers are available in two shapes to provide differentiating images and the ability to diagnose breast disease independently for multiple biopsy sites in a single breast.

“I like the fact that with the Celero, you can pre-fire directly to the lesion and you know you won’t fire past it,” said Dr. Heck. “It provides me with excellent specimens that our pathologists are very happy with and bleeding has not been an issue. Patient care is enhanced because we can make a definitive diagnosis much quicker. It’s the right thing to do and the way a breast center should operate.”

Dr. Quehuong Pham, General Surgeon at Inverness Surgical Associates in Inverness, Florida notes that the DP-6600 digital ultrasonic diagnostic imaging system gives breast surgeons the ability to provide comprehensive patient care in their office, without the need to refer patients to radiologists for imaging and possible wire localization for a later surgical procedure. “I see a significant benefit to what Hologic is offering as an ultrasound package,” said Dr. Pham. “Having the ability to image the breast, easily perform a biopsy and mark the biopsy site, and then also provide disease treatment with the MammoSite radiation therapy system, if necessary, really makes my practice very efficient and offers my patients convenience. Not only does this benefit me with scheduling, but also in planning my surgical cases.”

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic’s core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging.

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the anticipated benefits from its distribution agreement for the DP-6600 digital ultrasonic diagnostic imaging system with Mindray Medical International and the integration of Hologic’s product offerings, as well as the anticipated performance of this integrated product offering and each of the products included in that offering. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; the early stage of market development for this integrated offering; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; technical innovations that could render the technology or products under development obsolete; competition; and reimbursement policies for the use of products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. The risks included above or in Hologic’s filings are not exhaustive. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.

Celero, MammoSite, SecurMark, and Suros are trademarks and/or registered trademarks of Hologic and/or its subsidiaries in the U.S. and/or other countries.
Glycoprene is a registered trademark of Poly-Med, Inc.